Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
Primary Purpose
Lymphangioleiomyomatosis, Sleep Disorder, Sleep Apnea Syndromes
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
LAM patients underwent PSG
Sponsored by
About this trial
This is an interventional screening trial for Lymphangioleiomyomatosis
Eligibility Criteria
Inclusion Criteria:
- confirmed diagnosis of LAM according to current guidelines
- sign of informed consent to participate
Exclusion Criteria:
- the presence of either acute or chronic respiratory failure
- the use of long-term oxygen therapy
Sites / Locations
- Azienda Ospedaliero-Universitaria di BolognaRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PSG in LAM patients
Arm Description
Patients affected by LAM underwent whole-night PSG
Outcomes
Primary Outcome Measures
prevalence of sleep disorders in LAM
Aim of the project is to assess the presence of sleep disorders (oxygen destaruration during sleep and/or sleep apnea or hypopnea) in patients affected by LAM.
correlation between sleep-related disorders and LAM severity measured by spirometry
Another aim of the project is to stratify the presence of sleep-related disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to the severity of LAM measured through functional impairment. By spirometry performed at the time of PSG the study population will be divided in: subjects with obstructive impairment; subjects with restrictive abnormality and subjects with no alterations.
correlation between sleep-related disorders and LAM severity measured by annual decline of forced-expiratory volume at the first second (FEV1)
Another aim of the project is to stratify the presence of sleep-related disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to the severity of LAM measured by annual decline of forced-expiratory volume at the first second (FEV1), expressed in ml/year. Annual decline of FEV1 will be measured subtracting the FEV1 value (ml) at the time of PSG test to the FEV1 value (ml) at the time of diagnosis and then, dividing it by disease duration in years.
correlation between sleep-related disorders and LAM severity measured by arterial blood gas exchange
Another aim of the project is to stratify the presence of sleep-related disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to the severity of LAM measured through arterial blood gas exchanges values: partial pressure of oxygen (PaO2 - mmHg), partial pressure of carbon dioxide (PaCO2 - mmHg), oxygen saturation (SatO2, %).
correlation between sleep-related disorders and clincal parameters
Moreover, another aim is to assess the distribution of sleep disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to age, sex, body mass index (BMI), comorbidities in patients affected by LAM.
BMI will be calculated using height (mt) and weight (Kg) at the time of PSG and expressed in Kg/m^2.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04577937
Brief Title
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
Official Title
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 30, 2020 (Actual)
Primary Completion Date
July 8, 2021 (Anticipated)
Study Completion Date
November 1, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
dr. Stefano Nava
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Lymphangioleiomyomatosis (LAM) is a rare and progressive pulmonary disease of unknown etiology that almost exclusively affects women. It is characterised by cystic radiological lung pattern and by the possible presence of angiomyolipomas in other sites or organs. Functionally LAM is associated with airway obstruction or restriction and progressive hypoxemia up to chronic respiratory failure.
There are no studies, so far, which have investigated whether during sleep these patients show changes in the sleep profile and gas exchange and if these changes are related to disease severity. Aim of the study, prospective and pilot, is to evaluate whether the physiological modification of respiratory mechanics during sleep is associated with polysomnographic alterations in LAM.
Detailed Description
Lymphangioleiomiomatosis (LAM) is a rare progressive disease that affects primarily lungs with a cystic radiologic pattern and may be associated with angiomiolipomas in the kidneys or in other sites and an increased frequency of meningioma. Patients with sporadic LAM are usually female (incidence around 1/400.000 adult females). LAM associated with tuberous sclerosis may affect male, female and children.
LAM patients are functionally characterized by obstructive or restrictive syndrome that leads patients to hypoxemia and chronic respiratory failure, so that quality of Life (QoL) of these patients is affected by dyspnea. Hypoxemia contributes to the development of secondary pulmonary hypertension (PH) during progression of LAM history, worsening the damage.
The modifications in the neural control of ventilation during sleep in combination with anatomical disposition drive to sleep-related changes in upper airway resistance and physiologic desaturations. In healthy subjects these features are almost completely compensated but, in LAM patients, may lead to airway obstruction and/or pathologic oxygen desaturation that could be managed. So far, none have investigated the changes in sleep architecture and related blood gas exchange in patients with LAM relating these changes with disease severity.
This pilot study investigate if the physiologic modifications of breathing during sleep lead to sleep disorders in LAM patients, measured through abnormalities in polysomnography (PSG) and ih sleep disorders in LAM are associated with respiratory functional abnormalities and disease severity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphangioleiomyomatosis, Sleep Disorder, Sleep Apnea Syndromes, Hypopnea Syndrome
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
cohort study, pilot
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PSG in LAM patients
Arm Type
Experimental
Arm Description
Patients affected by LAM underwent whole-night PSG
Intervention Type
Diagnostic Test
Intervention Name(s)
LAM patients underwent PSG
Intervention Description
Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
Primary Outcome Measure Information:
Title
prevalence of sleep disorders in LAM
Description
Aim of the project is to assess the presence of sleep disorders (oxygen destaruration during sleep and/or sleep apnea or hypopnea) in patients affected by LAM.
Time Frame
1 year
Title
correlation between sleep-related disorders and LAM severity measured by spirometry
Description
Another aim of the project is to stratify the presence of sleep-related disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to the severity of LAM measured through functional impairment. By spirometry performed at the time of PSG the study population will be divided in: subjects with obstructive impairment; subjects with restrictive abnormality and subjects with no alterations.
Time Frame
1 year
Title
correlation between sleep-related disorders and LAM severity measured by annual decline of forced-expiratory volume at the first second (FEV1)
Description
Another aim of the project is to stratify the presence of sleep-related disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to the severity of LAM measured by annual decline of forced-expiratory volume at the first second (FEV1), expressed in ml/year. Annual decline of FEV1 will be measured subtracting the FEV1 value (ml) at the time of PSG test to the FEV1 value (ml) at the time of diagnosis and then, dividing it by disease duration in years.
Time Frame
1 year
Title
correlation between sleep-related disorders and LAM severity measured by arterial blood gas exchange
Description
Another aim of the project is to stratify the presence of sleep-related disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to the severity of LAM measured through arterial blood gas exchanges values: partial pressure of oxygen (PaO2 - mmHg), partial pressure of carbon dioxide (PaCO2 - mmHg), oxygen saturation (SatO2, %).
Time Frame
1 year
Title
correlation between sleep-related disorders and clincal parameters
Description
Moreover, another aim is to assess the distribution of sleep disorders (oxygen desaturation during sleep, sleep apnea or hypopnea) according to age, sex, body mass index (BMI), comorbidities in patients affected by LAM.
BMI will be calculated using height (mt) and weight (Kg) at the time of PSG and expressed in Kg/m^2.
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
confirmed diagnosis of LAM according to current guidelines
sign of informed consent to participate
Exclusion Criteria:
the presence of either acute or chronic respiratory failure
the use of long-term oxygen therapy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stefano Nava, MD-FERS
Phone
00390512143253
Email
stefano.nava@aosp.bo.it
First Name & Middle Initial & Last Name or Official Title & Degree
Irene Prediletto, MD-PhD
Phone
00390512143253
Email
irene.prediletto@aosp.bo.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefano Nava, MD-FERS
Organizational Affiliation
AOSP - Azienda Ospedaliero Universitaria Di Bologna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Azienda Ospedaliero-Universitaria di Bologna
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefano Nava, MD
Phone
00390512143253
Email
stefano.nava@aosp.bo.it
Phone
00390512143253
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
We'll reach out to this number within 24 hrs